[MCEMENT] YoY Cumulative Quarter Result on 30-Sep-2012 [#3]

Stock
[MCEMENT] MALAYAN CEMENT BERHAD
Announcement Date
22-Nov-2012
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2012
Quarter
30-Sep-2012 [#3]
Profit Trend
QoQ- 65.6%
YoY- 21.36%
Quarter Report
Latest QR
Upcoming QR
MCEMENT's Result
MCEMENT's Financial Summary
View:
Show?
Cumulative Result
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 CAGR
Revenue 2,032,515 2,058,478 2,101,826 2,049,916 1,895,713 1,707,704 1,858,623 1.50%
PBT 280,241 274,807 344,819 330,858 270,169 250,603 317,931 -2.08%
Tax -72,426 -68,444 -88,468 -87,501 -70,683 -38,879 -29,576 16.09%
NP 207,815 206,363 256,351 243,357 199,486 211,724 288,355 -5.31%
-
NP to SH 207,661 206,061 255,965 243,283 200,459 214,825 292,651 -5.55%
-
Tax Rate 25.84% 24.91% 25.66% 26.45% 26.16% 15.51% 9.30% -
Total Cost 1,824,700 1,852,115 1,845,475 1,806,559 1,696,227 1,495,980 1,570,268 2.53%
-
Net Worth 3,109,883 3,126,877 3,177,859 3,135,374 3,066,343 3,133,218 3,207,250 -0.51%
Dividend
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 CAGR
Div 203,926 220,920 67,975 203,926 203,856 135,857 2,552 107.46%
Div Payout % 98.20% 107.21% 26.56% 83.82% 101.69% 63.24% 0.87% -
Equity
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 CAGR
Net Worth 3,109,883 3,126,877 3,177,859 3,135,374 3,066,343 3,133,218 3,207,250 -0.51%
NOSH 849,695 849,695 849,695 849,695 849,402 849,110 850,729 -0.02%
Ratio Analysis
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 CAGR
NP Margin 10.22% 10.03% 12.20% 11.87% 10.52% 12.40% 15.51% -
ROE 6.68% 6.59% 8.05% 7.76% 6.54% 6.86% 9.12% -
Per Share
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 CAGR
RPS 239.21 242.26 247.36 241.25 223.18 201.12 218.47 1.52%
EPS 24.40 24.30 30.10 28.60 23.60 25.30 34.40 -5.56%
DPS 24.00 26.00 8.00 24.00 24.00 16.00 0.30 107.50%
NAPS 3.66 3.68 3.74 3.69 3.61 3.69 3.77 -0.49%
Adjusted Per Share Value based on latest NOSH - 849,695
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 CAGR
RPS 151.97 153.91 157.15 153.27 141.74 127.68 138.97 1.50%
EPS 15.53 15.41 19.14 18.19 14.99 16.06 21.88 -5.55%
DPS 15.25 16.52 5.08 15.25 15.24 10.16 0.19 107.62%
NAPS 2.3252 2.3379 2.376 2.3443 2.2927 2.3427 2.398 -0.51%
Price Multiplier on Financial Quarter End Date
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 CAGR
Date 30/09/15 30/09/14 30/09/13 28/09/12 30/09/11 30/09/10 30/09/09 -
Price 9.00 10.30 9.42 8.90 6.56 7.89 6.27 -
P/RPS 3.76 4.25 3.81 3.69 2.94 3.92 2.87 4.60%
P/EPS 36.83 42.47 31.27 31.08 27.80 31.19 18.23 12.42%
EY 2.72 2.35 3.20 3.22 3.60 3.21 5.49 -11.04%
DY 2.67 2.52 0.85 2.70 3.66 2.03 0.05 93.99%
P/NAPS 2.46 2.80 2.52 2.41 1.82 2.14 1.66 6.77%
Price Multiplier on Announcement Date
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 30/09/10 30/09/09 CAGR
Date 18/11/15 18/11/14 19/11/13 22/11/12 22/11/11 29/11/10 19/11/09 -
Price 9.20 10.14 9.85 9.62 6.59 7.90 6.20 -
P/RPS 3.85 4.19 3.98 3.99 2.95 3.93 2.84 5.19%
P/EPS 37.64 41.81 32.70 33.60 27.92 31.23 18.02 13.05%
EY 2.66 2.39 3.06 2.98 3.58 3.20 5.55 -11.53%
DY 2.61 2.56 0.81 2.49 3.64 2.03 0.05 93.26%
P/NAPS 2.51 2.76 2.63 2.61 1.83 2.14 1.64 7.34%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment